ReviewCell death discovery2025
BRPF1 in cancer epigenetics: a key regulator of histone acetylation and a promising therapeutic target.
Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structure, function, and pathology of PHF23.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Bromodomain and PHD finger-containing protein 1 (BRPF1) is an essential component of histone acetyltransferase complexes, where it acts as a scaffold to facilitate their assembly and enzymatic activity, thereby playing a key role in chromatin remodeling and transcriptional regulation. Emerging evidence indicates that BRPF1 is frequently dysregulated in cancer and contributes to tumorigenesis by modulating key oncogenic pathways. Its overexpression has been associated with poor prognosis in multiple malignancies, highlighting its relevance as a candidate for targeted therapy. Specifically, BRPF1 is particularly implicated in cancers of gastrointestinal and genitourinary systems, as well as in brain, skin, breast, and hematological tumors. The development of selective BRPF1 bromodomain inhibitors has opened new therapeutic avenues, with preclinical models showing notable anticancer effects. Moreover, combinatorial strategies involving BRPF1 inhibitors and other targeted therapies have shown promise in enhancing treatment efficacy. This review provides a comprehensive overview of BRPF1 structure and function, its oncogenic role, and the therapeutic targeting strategies. We also examined current advancements in drug development, highlighting the challenges in BRPF1 inhibition, and proposed future research directions to elucidate its role in cancer epigenetics and translate these insights into improved clinical outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.